Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seattle Genetics Looking To Improve, Replace Standards Of Care

Executive Summary

Seattle Genetics is transitioning from a one-product to multi-product company while growing its established Adcetris franchise. New studies are coming for three additional antibody-drug conjugates aimed at solid tumors.

Advertisement

Related Content

Keeping Track: Yupelri Is Latest Novel Drug Approved, But Bad News For Biosimilars
Breakthrough Status Arrives Late In Development Of Yervoy+Opdivo, Enfortumab Vedotin And Pedmark
Seattle Genetics Says Adcetris Sets New Standard In Frontline Lymphoma
ASH In Review: Roche Refreshes Hematology Portfolio With Robust New Drugs
GSK's Oncology R&D Head: GSK2857916 'Proves We're Still Here And Serious'
And Then There Were Five: Roche's Tecentriq Joins Europe I-O Race
A CASCADE Of Trouble For Seattle Genetics' AML Drug SGN-CD33A
The Bar Is Raised At ASCO For ADC Developers
INTERVIEW: I-SPY 2 investigator on cancer study, Synta's ganetespib
BioNotebook: Seattle Genetics/AbbVie, Auspex, Flexion, Ironwood

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100286

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel